Hitachi Chemical inks Daiichi Sankyo regenerative meds deal

By Flora Southey

- Last updated on GMT

Daiichi Sankyo has selected CDMO Hitachi Chemical Therapeutics Solutions to make regenerative medicine for the Japanese market.

Under the clinical manufacturing agreement, Hitachi Chemical will make Daiichi Sankyo’s investigative product at its facility in Yokohama City, Kanagawa Prefecture.

The site houses Hitachi Chemical’s PCT regenerative cell-focused service platform, which its off-shoot Hitachi Chemical Co. America purchased​ from majority shareholder Caladrius Biosciences last year.

Regenerative medicine describes the process of transplanting in-vitro ​cells into patients to help restore organ or immune functions affected by disease. Regenerative approaches include immunotherapy and somatic stem cell therapies, engineered immune cell therapy and induced pluripotent stem cells (iPSC).

Daiichi Sankyo spokesperson Koji Ogiwara did not disclose which investigational drug will be manufactured by Hitachi Chemical, nor did he provide details on the manufacturing timeframe.

In October last year, Hitachi Chemical announced plans​ to add 49,700 sq. ft. to its PCT service site in Allendale, New Jersey, US.

The firm also announced plans to upgrade its Pearl Court site in Allendale, and confirmed its regenerative cell-focused CDMO site in Yokohama would be validated by April this year.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers